Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 41333

AbstractMaterial and MethodsResultsDiscussionConclusionReferencesDOI and Others
Article in PDF How to Cite Citation Manager Readers' Comments (0) Audio Visual Article Statistics Link to PUBMED Print this Article Send to a Friend
Advertisers Access Statistics Resources

Dr Mohan Z Mani

"Thank you very much for having published my article in record time.I would like to compliment you and your entire staff for your promptness, courtesy, and willingness to be customer friendly, which is quite unusual.I was given your reference by a colleague in pathology,and was able to directly phone your editorial office for clarifications.I would particularly like to thank the publication managers and the Assistant Editor who were following up my article. I would also like to thank you for adjusting the money I paid initially into payment for my modified article,and refunding the balance.
I wish all success to your journal and look forward to sending you any suitable similar article in future"



Dr Mohan Z Mani,
Professor & Head,
Department of Dermatolgy,
Believers Church Medical College,
Thiruvalla, Kerala
On Sep 2018




Prof. Somashekhar Nimbalkar

"Over the last few years, we have published our research regularly in Journal of Clinical and Diagnostic Research. Having published in more than 20 high impact journals over the last five years including several high impact ones and reviewing articles for even more journals across my fields of interest, we value our published work in JCDR for their high standards in publishing scientific articles. The ease of submission, the rapid reviews in under a month, the high quality of their reviewers and keen attention to the final process of proofs and publication, ensure that there are no mistakes in the final article. We have been asked clarifications on several occasions and have been happy to provide them and it exemplifies the commitment to quality of the team at JCDR."



Prof. Somashekhar Nimbalkar
Head, Department of Pediatrics, Pramukhswami Medical College, Karamsad
Chairman, Research Group, Charutar Arogya Mandal, Karamsad
National Joint Coordinator - Advanced IAP NNF NRP Program
Ex-Member, Governing Body, National Neonatology Forum, New Delhi
Ex-President - National Neonatology Forum Gujarat State Chapter
Department of Pediatrics, Pramukhswami Medical College, Karamsad, Anand, Gujarat.
On Sep 2018




Dr. Kalyani R

"Journal of Clinical and Diagnostic Research is at present a well-known Indian originated scientific journal which started with a humble beginning. I have been associated with this journal since many years. I appreciate the Editor, Dr. Hemant Jain, for his constant effort in bringing up this journal to the present status right from the scratch. The journal is multidisciplinary. It encourages in publishing the scientific articles from postgraduates and also the beginners who start their career. At the same time the journal also caters for the high quality articles from specialty and super-specialty researchers. Hence it provides a platform for the scientist and researchers to publish. The other aspect of it is, the readers get the information regarding the most recent developments in science which can be used for teaching, research, treating patients and to some extent take preventive measures against certain diseases. The journal is contributing immensely to the society at national and international level."



Dr Kalyani R
Professor and Head
Department of Pathology
Sri Devaraj Urs Medical College
Sri Devaraj Urs Academy of Higher Education and Research , Kolar, Karnataka
On Sep 2018




Dr. Saumya Navit

"As a peer-reviewed journal, the Journal of Clinical and Diagnostic Research provides an opportunity to researchers, scientists and budding professionals to explore the developments in the field of medicine and dentistry and their varied specialities, thus extending our view on biological diversities of living species in relation to medicine.
‘Knowledge is treasure of a wise man.’ The free access of this journal provides an immense scope of learning for the both the old and the young in field of medicine and dentistry as well. The multidisciplinary nature of the journal makes it a better platform to absorb all that is being researched and developed. The publication process is systematic and professional. Online submission, publication and peer reviewing makes it a user-friendly journal.
As an experienced dentist and an academician, I proudly recommend this journal to the dental fraternity as a good quality open access platform for rapid communication of their cutting-edge research progress and discovery.
I wish JCDR a great success and I hope that journal will soar higher with the passing time."



Dr Saumya Navit
Professor and Head
Department of Pediatric Dentistry
Saraswati Dental College
Lucknow
On Sep 2018




Dr. Arunava Biswas

"My sincere attachment with JCDR as an author as well as reviewer is a learning experience . Their systematic approach in publication of article in various categories is really praiseworthy.
Their prompt and timely response to review's query and the manner in which they have set the reviewing process helps in extracting the best possible scientific writings for publication.
It's a honour and pride to be a part of the JCDR team. My very best wishes to JCDR and hope it will sparkle up above the sky as a high indexed journal in near future."



Dr. Arunava Biswas
MD, DM (Clinical Pharmacology)
Assistant Professor
Department of Pharmacology
Calcutta National Medical College & Hospital , Kolkata




Dr. C.S. Ramesh Babu
" Journal of Clinical and Diagnostic Research (JCDR) is a multi-specialty medical and dental journal publishing high quality research articles in almost all branches of medicine. The quality of printing of figures and tables is excellent and comparable to any International journal. An added advantage is nominal publication charges and monthly issue of the journal and more chances of an article being accepted for publication. Moreover being a multi-specialty journal an article concerning a particular specialty has a wider reach of readers of other related specialties also. As an author and reviewer for several years I find this Journal most suitable and highly recommend this Journal."
Best regards,
C.S. Ramesh Babu,
Associate Professor of Anatomy,
Muzaffarnagar Medical College,
Muzaffarnagar.
On Aug 2018




Dr. Arundhathi. S
"Journal of Clinical and Diagnostic Research (JCDR) is a reputed peer reviewed journal and is constantly involved in publishing high quality research articles related to medicine. Its been a great pleasure to be associated with this esteemed journal as a reviewer and as an author for a couple of years. The editorial board consists of many dedicated and reputed experts as its members and they are doing an appreciable work in guiding budding researchers. JCDR is doing a commendable job in scientific research by promoting excellent quality research & review articles and case reports & series. The reviewers provide appropriate suggestions that improve the quality of articles. I strongly recommend my fraternity to encourage JCDR by contributing their valuable research work in this widely accepted, user friendly journal. I hope my collaboration with JCDR will continue for a long time".



Dr. Arundhathi. S
MBBS, MD (Pathology),
Sanjay Gandhi institute of trauma and orthopedics,
Bengaluru.
On Aug 2018




Dr. Mamta Gupta,
"It gives me great pleasure to be associated with JCDR, since last 2-3 years. Since then I have authored, co-authored and reviewed about 25 articles in JCDR. I thank JCDR for giving me an opportunity to improve my own skills as an author and a reviewer.
It 's a multispecialty journal, publishing high quality articles. It gives a platform to the authors to publish their research work which can be available for everyone across the globe to read. The best thing about JCDR is that the full articles of all medical specialties are available as pdf/html for reading free of cost or without institutional subscription, which is not there for other journals. For those who have problem in writing manuscript or do statistical work, JCDR comes for their rescue.
The journal has a monthly publication and the articles are published quite fast. In time compared to other journals. The on-line first publication is also a great advantage and facility to review one's own articles before going to print. The response to any query and permission if required, is quite fast; this is quite commendable. I have a very good experience about seeking quick permission for quoting a photograph (Fig.) from a JCDR article for my chapter authored in an E book. I never thought it would be so easy. No hassles.
Reviewing articles is no less a pain staking process and requires in depth perception, knowledge about the topic for review. It requires time and concentration, yet I enjoy doing it. The JCDR website especially for the reviewers is quite user friendly. My suggestions for improving the journal is, more strict review process, so that only high quality articles are published. I find a a good number of articles in Obst. Gynae, hence, a new journal for this specialty titled JCDR-OG can be started. May be a bimonthly or quarterly publication to begin with. Only selected articles should find a place in it.
An yearly reward for the best article authored can also incentivize the authors. Though the process of finding the best article will be not be very easy. I do not know how reviewing process can be improved. If an article is being reviewed by two reviewers, then opinion of one can be communicated to the other or the final opinion of the editor can be communicated to the reviewer if requested for. This will help one’s reviewing skills.
My best wishes to Dr. Hemant Jain and all the editorial staff of JCDR for their untiring efforts to bring out this journal. I strongly recommend medical fraternity to publish their valuable research work in this esteemed journal, JCDR".



Dr. Mamta Gupta
Consultant
(Ex HOD Obs &Gynae, Hindu Rao Hospital and associated NDMC Medical College, Delhi)
Aug 2018




Dr. Rajendra Kumar Ghritlaharey

"I wish to thank Dr. Hemant Jain, Editor-in-Chief Journal of Clinical and Diagnostic Research (JCDR), for asking me to write up few words.
Writing is the representation of language in a textual medium i e; into the words and sentences on paper. Quality medical manuscript writing in particular, demands not only a high-quality research, but also requires accurate and concise communication of findings and conclusions, with adherence to particular journal guidelines. In medical field whether working in teaching, private, or in corporate institution, everyone wants to excel in his / her own field and get recognised by making manuscripts publication.


Authors are the souls of any journal, and deserve much respect. To publish a journal manuscripts are needed from authors. Authors have a great responsibility for producing facts of their work in terms of number and results truthfully and an individual honesty is expected from authors in this regards. Both ways its true "No authors-No manuscripts-No journals" and "No journals–No manuscripts–No authors". Reviewing a manuscript is also a very responsible and important task of any peer-reviewed journal and to be taken seriously. It needs knowledge on the subject, sincerity, honesty and determination. Although the process of reviewing a manuscript is a time consuming task butit is expected to give one's best remarks within the time frame of the journal.
Salient features of the JCDR: It is a biomedical, multidisciplinary (including all medical and dental specialities), e-journal, with wide scope and extensive author support. At the same time, a free text of manuscript is available in HTML and PDF format. There is fast growing authorship and readership with JCDR as this can be judged by the number of articles published in it i e; in Feb 2007 of its first issue, it contained 5 articles only, and now in its recent volume published in April 2011, it contained 67 manuscripts. This e-journal is fulfilling the commitments and objectives sincerely, (as stated by Editor-in-chief in his preface to first edition) i e; to encourage physicians through the internet, especially from the developing countries who witness a spectrum of disease and acquire a wealth of knowledge to publish their experiences to benefit the medical community in patients care. I also feel that many of us have work of substance, newer ideas, adequate clinical materials but poor in medical writing and hesitation to submit the work and need help. JCDR provides authors help in this regards.
Timely publication of journal: Publication of manuscripts and bringing out the issue in time is one of the positive aspects of JCDR and is possible with strong support team in terms of peer reviewers, proof reading, language check, computer operators, etc. This is one of the great reasons for authors to submit their work with JCDR. Another best part of JCDR is "Online first Publications" facilities available for the authors. This facility not only provides the prompt publications of the manuscripts but at the same time also early availability of the manuscripts for the readers.
Indexation and online availability: Indexation transforms the journal in some sense from its local ownership to the worldwide professional community and to the public.JCDR is indexed with Embase & EMbiology, Google Scholar, Index Copernicus, Chemical Abstracts Service, Journal seek Database, Indian Science Abstracts, to name few of them. Manuscriptspublished in JCDR are available on major search engines ie; google, yahoo, msn.
In the era of fast growing newer technologies, and in computer and internet friendly environment the manuscripts preparation, submission, review, revision, etc and all can be done and checked with a click from all corer of the world, at any time. Of course there is always a scope for improvement in every field and none is perfect. To progress, one needs to identify the areas of one's weakness and to strengthen them.
It is well said that "happy beginning is half done" and it fits perfectly with JCDR. It has grown considerably and I feel it has already grown up from its infancy to adolescence, achieving the status of standard online e-journal form Indian continent since its inception in Feb 2007. This had been made possible due to the efforts and the hard work put in it. The way the JCDR is improving with every new volume, with good quality original manuscripts, makes it a quality journal for readers. I must thank and congratulate Dr Hemant Jain, Editor-in-Chief JCDR and his team for their sincere efforts, dedication, and determination for making JCDR a fast growing journal.
Every one of us: authors, reviewers, editors, and publisher are responsible for enhancing the stature of the journal. I wish for a great success for JCDR."



Thanking you
With sincere regards
Dr. Rajendra Kumar Ghritlaharey, M.S., M. Ch., FAIS
Associate Professor,
Department of Paediatric Surgery, Gandhi Medical College & Associated
Kamla Nehru & Hamidia Hospitals Bhopal, Madhya Pradesh 462 001 (India)
E-mail: drrajendrak1@rediffmail.com
On May 11,2011




Dr. Shankar P.R.

"On looking back through my Gmail archives after being requested by the journal to write a short editorial about my experiences of publishing with the Journal of Clinical and Diagnostic Research (JCDR), I came across an e-mail from Dr. Hemant Jain, Editor, in March 2007, which introduced the new electronic journal. The main features of the journal which were outlined in the e-mail were extensive author support, cash rewards, the peer review process, and other salient features of the journal.
Over a span of over four years, we (I and my colleagues) have published around 25 articles in the journal. In this editorial, I plan to briefly discuss my experiences of publishing with JCDR and the strengths of the journal and to finally address the areas for improvement.
My experiences of publishing with JCDR: Overall, my experiences of publishing withJCDR have been positive. The best point about the journal is that it responds to queries from the author. This may seem to be simple and not too much to ask for, but unfortunately, many journals in the subcontinent and from many developing countries do not respond or they respond with a long delay to the queries from the authors 1. The reasons could be many, including lack of optimal secretarial and other support. Another problem with many journals is the slowness of the review process. Editorial processing and peer review can take anywhere between a year to two years with some journals. Also, some journals do not keep the contributors informed about the progress of the review process. Due to the long review process, the articles can lose their relevance and topicality. A major benefit with JCDR is the timeliness and promptness of its response. In Dr Jain's e-mail which was sent to me in 2007, before the introduction of the Pre-publishing system, he had stated that he had received my submission and that he would get back to me within seven days and he did!
Most of the manuscripts are published within 3 to 4 months of their submission if they are found to be suitable after the review process. JCDR is published bimonthly and the accepted articles were usually published in the next issue. Recently, due to the increased volume of the submissions, the review process has become slower and it ?? Section can take from 4 to 6 months for the articles to be reviewed. The journal has an extensive author support system and it has recently introduced a paid expedited review process. The journal also mentions the average time for processing the manuscript under different submission systems - regular submission and expedited review.
Strengths of the journal: The journal has an online first facility in which the accepted manuscripts may be published on the website before being included in a regular issue of the journal. This cuts down the time between their acceptance and the publication. The journal is indexed in many databases, though not in PubMed. The editorial board should now take steps to index the journal in PubMed. The journal has a system of notifying readers through e-mail when a new issue is released. Also, the articles are available in both the HTML and the PDF formats. I especially like the new and colorful page format of the journal. Also, the access statistics of the articles are available. The prepublication and the manuscript tracking system are also helpful for the authors.
Areas for improvement: In certain cases, I felt that the peer review process of the manuscripts was not up to international standards and that it should be strengthened. Also, the number of manuscripts in an issue is high and it may be difficult for readers to go through all of them. The journal can consider tightening of the peer review process and increasing the quality standards for the acceptance of the manuscripts. I faced occasional problems with the online manuscript submission (Pre-publishing) system, which have to be addressed.
Overall, the publishing process with JCDR has been smooth, quick and relatively hassle free and I can recommend other authors to consider the journal as an outlet for their work."



Dr. P. Ravi Shankar
KIST Medical College, P.O. Box 14142, Kathmandu, Nepal.
E-mail: ravi.dr.shankar@gmail.com
On April 2011
Anuradha

Dear team JCDR, I would like to thank you for the very professional and polite service provided by everyone at JCDR. While i have been in the field of writing and editing for sometime, this has been my first attempt in publishing a scientific paper.Thank you for hand-holding me through the process.


Dr. Anuradha
E-mail: anuradha2nittur@gmail.com
On Jan 2020

Important Notice

Original article / research
Year : 2024 | Month : January | Volume : 18 | Issue : 1 | Page : DC13 - DC18 Full Version

Targeting the Enterococcal Fibronectin Binding Protein- A of Enterococcus faecalis with Bioactive Compounds from Aegle Marmelos: An In-vitro and In-silico Pilot Study


Published: January 1, 2024 | DOI: https://doi.org/10.7860/JCDR/2024/66306.18973
Vishaka Kothari, AS Smiline Girija, Shoba Gunasekaran, J Vijayashree Priyadharsini

1. Undergraduate Student, Department of Microbiology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, Tamil Nadu, India. 2. Professor, Department of Microbiology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, Tamil Nadu, India. 3. Assistant Professor, Department of Biotechnology, Dwaraka Doss Goverdhan Doss Vaishnav College, Chennai, Tamil Nadu, India. 4. Associate Professor, Department of Microbiology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, Tamil Nadu, India.

Correspondence Address :
Dr. AS Smiline Girija,
Professor, Department of Microbiology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai-600077, Tamil Nadu, India.
E-mail: smilinejames25@gmail.com

Abstract

Introduction: Enterococcus faecalis (E. faecalis) is a significant endodontic pathogen, and its virulence has been shown to be significantly influenced by Enterococcal fibronectin binding protein-A (EfbA). Targeting this virulent protein using alternative strategies would be a novel idea to combat the complications of E. faecalis in dental healthcare settings. Thus, the rationale of this investigation is to identify potent bioactive compounds from Aegle marmelos for their antimicrobial properties against EfbA of E. faecalis.

Aim: To assess the frequency of EfbA among clinical isolates of E. faecalis and evaluate the antibacterial activity of essential bioactive compounds from Aegle marmelos.

Materials and Methods: An in-vitro and in-silico pilot study was conducted from April 2022 to June 2022 in the Department of Microbiology, Saveetha Dental College and Hospitals, Chennai, Tamil Nadu, India to detect the frequency of EfbA in E. faecalis. Patients with typical root caries were included. Microbiological processing of 20 root caries samples was performed to characterise E. faecalis and detect the EfbA gene using Polymerase Chain Reaction (PCR) amplification. Crude methanol extract was obtained from A. marmelos and assessed for its antimicrobial effect against the isolated strains of E. faecalis. Furthermore, several biomolecules from A. marmelos were evaluated for their inhibitory properties through in-silico docking analysis.

Results: E. faecalis was identified in 12 (60%) out of 20 root caries samples, and three isolates (25%) were identified as Multidrug-Resistant (MDR) strains based on the antibiogram susceptibility profile, showing resistance to more than three different tested antibiotic groups. EfbA was detected in two of the three MDR strains (66.7%). The crude extract of A. marmelos exhibited promising antibacterial activity. In-silico analysis of the essential oil compounds from A. marmelos revealed that Aegeline had a high interaction with low docking energy and a high number of hydrogen bonds.

Conclusion: The current study highlights the potential of aegeline from A. marmelos as an antibacterial agent against resistant strains of E. faecalis. However, additional in-vivo research must be conducted to experimentally validate these findings.

Keywords

Aegeline, Health, Virulence

Enterococcus faecalis, a Gram-positive Group D Streptococcus, has become an opportunistic pathogen and has contributed significantly to healthcare-associated infections since the late 1970s (1). E. faecalis is considered the most prevalent species in endodontic infections, with associated complications such as endocarditis (2). Due to its propensity for MDR against routine antibiotics like aminoglycosides, treating enterococcal endocarditis has been clinically challenging, with a mortality rate of up to 20% (3). In addition to its drug-resistant properties, many virulent factors are known to contribute to its pathogenesis and the development of systemic infections and oral mucosal diseases (4).

Among various pathogenic mechanisms in E. faecalis, bacterial adhesion is a critical stage in disease development as it facilitates colonisation and penetration of the mucosal barrier, ultimately leading to subcellular spread within the host. Similar to other Gram-positive bacteria such as Staphylococcus aureus, E. faecalis is highly virulent and possesses specific adhesins called Microbial Surface Component-Recognising Adhesive Matrix Molecules (MSCRAMMs), which aid in attachment to human receptors or various Extracellular Matrix (ECM) components (5). Numerous adhesins have been documented in E. faecalis, with the first characterised adhesin being EfbA, a PavA-like fibronectin-binding protein encoded by the EF1249 gene, which was initially reported in the JH2-2 strain of E. faecalis (6). Its role was demonstrated through mutation-related studies, where an isogenic deletion mutant for EfbA showed severe impairment in its ability to bind to immobilised human fibronectin. EfbA plays a role in the pathogenesis of enterococcal Urinary Tract Infections (UTIs), and experimental evidence suggests that immunisation against EfbA can prevent infective endocarditis (7). Targeting EfbA in E. faecalis could be a novel approach to overcome the complications caused by the organism in all healthcare settings.

In this context, the identification of potential novel bioactive compounds from natural sources to combat the pathogenic mechanisms in virulent, and resistance traits of E. faecalis has gained significant interest in recent years. The Rutaceae plant Aegle marmelos (L.) Correa, commonly known as Bael, has been extensively used in traditional Indian medical practices. A. marmelos is indigenous to Northern India but is also grown in other parts of the Indian subcontinent, including Ceylon, Burma, Bangladesh, Thailand, and Indo-China. Reports suggest that A. marmelos contains various phytoconstituents, primarily aegelin and marmelin, along with small amounts of tannin and riboflavin. Many compounds from A. marmelos are known for their bioactive properties, providing protection against various systemic ailments (8). Therefore, the hypothesis of this study aims to evaluate the antimicrobial properties of crude extracts from A. marmelos against clinical strains of E. faecalis.

E. faecalis
is associated with endocarditis, and novel alternative therapeutic strategies utilising potent bioactive compounds from natural sources offer promising methods to control these infections. In this context, the selection of active compounds can be effectively achieved using computational tools and databases. Numerous studies have documented the evaluation of various parameters of bioactive compounds derived from plants to observe promising drug-ligand interactions [9,10]. This study is unique as it implements the investigation for the first time to identify potent compounds from A. marmelos against EfbA of E. faecalis. As a pilot study, the aim of this investigation was to target the EfbA protein using bioactive compounds from A. marmelos through in-vitro assays to assess antimicrobial efficacy and a computational approach to analyse drug-ligand interactions.

Material and Methods

This in-vitro and in-silico pilot study was conducted from April 2022 to June 2022, spanning a three-month period, in the Department of Microbiology at Saveetha Dental College and Hospitals, Chennai, Tamil Nadu, India. Prior to the start of the investigation, Institutional Ethical clearance was obtained (Ref No: SRB/SDC/UG-2077/21/MICRO/056; IHEC/SDC/UG-2077/21/MICRO/597). Since this was a pilot study, statistical analysis for power calculation was not performed.

Twenty individuals who reported having root caries, as examined by an endodontist, had their carious scrapings collected. Sample collection was conducted with the informed consent of the patients and approval from the institutional review board. The carious dentine was immediately transferred to the microbiology lab after collection and placed in sterile trypticase soy broth. The samples were then plated onto clean Brain Heart Infusion (BHI) Agar and incubated for 24 hours at 37°C. Following incubation, the colonies were identified through routine biochemical testing, colony morphology, and gram staining.

Antimicrobial susceptibility tests: The clinical strains isolated from the samples were subjected to antibiotic susceptibility profiling to evaluate the antibiogram pattern. Briefly, a lawn culture of the fresh broth suspension of E. faecalis was prepared on Mueller Hinton agar, and antibiotics as per the Clinical and Laboratory Standards Institute (CLSI) guidelines for 2021 (11) were placed on the surface of the lawn using sterile forceps. The included antibiotics were amoxyclav (30 μg), ceftriaxone (30 μg), cefoperazone-sulbactam (75/30 μg), clindamycin (2 μg), cefixime (5 μg), levofloxacin (5 μg), linezolid (30 μg), vancomycin (30 μg), azithromycin (15 μg), amikacin, tetracycline (30 μg), ciprofloxacin (5 μg), cefoperazone (2 μg), and gentamicin (10 μg). The plates were then incubated at 37°C for 24 hours, and the zones of inhibition on the plates were measured to determine the patterns of susceptibility.

Genotypic characterisation of EfbAgene in E. faecalis: The clinical strains that were resistant to more than three groups of drugs tested were isolated on MacConkey agar after 24 hours of incubation at 37°C. Genomic DNA was extracted from the E. faecalis strains following the manufacturer’s instructions using a Qiagen kit. PCR was performed to detect the presence of EfbA. For the PCR reaction, 7.8 μL of 2 μL master mix from (Takara, Japan) was combined with 5.6 μL of DDW. A 15 μL reaction mixture was prepared using specific primers for EfbA (F: GCACAAGTCCCAAAAGGAGC and R: AAGTGCGGCTTCAGTAAGGG) at a concentration of 0.31 μL of 100 pmol/mL (Eurofins Genomic India Pvt., Ltd., Bangalore). The amplification was carried out using Germany’s Eppendorf thermocycler with 35 cycles at an annealing temperature of 58°C. The resulting amplicon was visualised using a gel documentation system and examined on a 1% agarose gel electrophoresis with Ethidium bromide. The size of the amplicon was determined using a 100 bp DNA ladder from New England Biolabs.

Preparation of the A. marmelos extract: Fresh A. marmelos fruits were purchased from the neighborhood markets. The fruits were externally cleaned by washing them three times in sterile distilled water. Then, they were chopped into small pieces using sterilised knives and dried in the shade. After drying, the fruits were mechanically milled into a coarse powder. The powder was then stored in sterile containers for further antibacterial bioassay (12).

Next, 10 grams of the dried A. marmelos leaf powder was mixed with 100 mL of methanol and incubated at room temperature for a week with intermittent shaking. After the incubation period, the extract was filtered using a Whatman No. 1 filter. The filtered extract was placed onto sterile petri dishes and evaporated to obtain the crude extracts. These extracts were preserved at 4°C for additional in-vitro assays.

Antimicrobial bioassay: For the final formulation, 20 mg of the A. marmelos crude extract was combined with 1 mL of Dimethyl Sulphoxide (DMSO) and vortexed. The clinical strains of E. faecalis were cultured as a lawn on sterile Saboraud’s dextrose agar, and the wells were punctured using a sterile agar cutter (13). Then, 50 μL of the diluted extract was added to each well, and the plates were incubated for 48 hours at 37°C. After incubation, the size of the zones was measured and recorded using a HiMedia antibiotic measuring scale. The test was repeated three times with different concentrations of 20, 10, and 5 mg/mL, and the mean value was recorded.

Retrieval of EfbAand protein optimisation: The crystal structure of the EfbA protein was provided by the Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank (PDB) (http://www.rcsb.org/pdb) (14). By adding hydrogen atoms, the crystal structure of EfbA was optimised. The AutoDock program, version 1.5.6, was used to assign electrical charges to the protein atoms, and the RASMOL tool was used to visualise the three-dimensional structure of the EfbA protein.

Ligand preparation and optimisation: ChemSketch software was used to obtain the chemical structures of A. marmelos bioactive derivatives, as done in earlier studies [15,16]. Afterward, the 3D structures were optimised. The open-label molecular converter program underwent additional conversions on the chosen ligands. After that, they were stored in PDB format. The chosen ligands were subsequently saved in molecular structural formats.

Molinspiration assessment of the selected ligands: The Molinspiration evaluation software was used to determine the counts of hydrogen bond acceptors and donors in connection with the membrane permeability and bioavailability of the compounds, as well as the partition coefficient (logP) and molecular weight of the compounds as basic molecular descriptors. The Lipinski’s Rule of Five was employed to further examine the characteristics of the selected bio compounds’ absorption, distribution, metabolism, and elimination.

Docking interactions: To assess the affinity between bio-compounds from A. marmelos and the E. faecalis EfbA protein, docking analysis was performed using the AutoDock tool, and the interaction scores were further evaluated.

Docking visualisation: The hydrogen bond interactions between the bio-compounds of A. marmelos and EfbA of E. faecalis were visualised using discovery studio visualiser. The relative stabilities were assessed through additional docking score evaluations, binding affinities, molecular dynamics, and energy simulations.

Statistical Analysis

The statistical significance of the results was evaluated using SPSS version 21.0 (Chicago, IL).

Results

Characterisation of E. faecalis: From a total of 20 samples processed, 12 strains (60%) of E. faecalis were identified. The E. faecalis colonies were identified as pinpoint colonies on the BHI agar plates. Gram staining revealed typical diplococci that are gram-positive and have pairs of oval cocci. Phenotypic characterisation studies revealed colonies with positive bile esculin hydrolysis but negative catalase (Table/Fig 1).

Three isolates (25%) were identified as MDR strains based on the antibiogram susceptibility profile, showing resistance to more than three different tested antibiotic groups. Two out of the three MDR strains (66.7%) tested positive for EfbA, with an amplicon size of 510 bp (Table/Fig 2).

Antifungal effect of A. marmelos extract: The total yield of the A. marmelos methanol extract from 100 g of the crude powder was 23 mg (w/v). The extract exhibited a promising effect against all the sensitive strains (n=9) and the clinical strains (n=3) with zone sizes of 18 mm, 13 mm, and 10 mm for 20 mg, 10 mg, and 5 mg, respectively.

Structural retrieval of the EfbAprotein from E. faecalis: The UNIPROT database was searched for the FASTA sequence of EfbA from E. faecalis, and the sequence ID was A0A335NTF8. A homology model was created using the Swissmodel server, utilising the template 5WQO-A chain. With a 100% sequence identity to the template, the model appeared quite plausible. Moreover, the Ramachandran plot demonstrated that 88.1% of residues were located in the most favorable regions, with none falling within the restricted zones (Table/Fig 3). The 3D structure of EfbA was visualised using RASMOL, where the alpha-helices were represented in pink, the beta sheets in yellow arrows, and the turns in white colour.

Structural retrieval of the ligands from compounds in A. marmelos essential oils: To perform ligand optimisation, ACD Chemsketch was utilised, and the Open Babel molecular converter tool was used to obtain a compatible format. (Table/Fig 4) presents the 2D and 3D structures, as well as the Simplified Molecular Input Line Entry System (SMILES) format, of the ligands extracted from A. marmelos.

Molinspiration assessment towards drug likeliness: Based on the calculation of ion channel modulation, GPCR ligand, nuclear receptor ligand, kinase inhibitor, enzyme inhibition, and protease inhibition, the bioactivity score prediction of essential compounds of A. marmelos against EfbA of E. faecalis was assessed for drug likeliness, and the results were tabulated in (Table/Fig 5).

Docking analysis of the A. marmelos derivatives against EfbAof E. faecalis: LGA was employed to select the finest conformers. (Table/Fig 6) presents the interactions of the EfbA protein with bioactive substances from A. marmelos. Docking scores, hydrogen bond counts, and torsional energy between the ligands and the drugs were recorded as data (Table/Fig 7). The overall docking energies and interactions between EfbA and the A. marmelos biocompounds were assessed using ligand efficiency, intermolecular energy, electrostatic energy, vdW + Hbond + desolv energy, internal energy, and torsional energy in kcal/mol (Table/Fig 8). The results indicate that the imidazole molecule from A. marmelos exhibited the most promising interaction due to its low binding energy. Additionally, alkyl/p-alkyl interactions, van der Waals, p-sulfur interactions, and p-r interactions were observed.

Discussion

Enterococci are considered transient members of the oral microbiome and can contribute to various systemic and oral-dental disorders. The presence of MDR and virulent traits makes Enterococci a challenging nosocomial pathogen for healthcare professionals. Enterococci are also part of the functional biomes of the gut and oral cavity (17). Limited studies have been conducted on the prevalence of E. faecalis strains carrying EfbA genetic determinants in healthcare settings. Therefore, this study aimed to assess the prevalence of these determinants among clinical isolates from patients with endodontic infections. Resistance among E. faecalis strains has been frequently reported, and present study observed a prevalence of 60% for E. faecalis among patients with root caries, with 25% of the strains exhibiting MDR. Among the resistant strains, 66.7% were found to possess the EfbA gene. This finding aligns with a previous study that associated the virulent EfbA gene with MDR, where the presence of EfbA was documented in 97.1% of resistant strains (18).

Plant-based biocompounds have been recognised for their potent bioactive properties and their effectiveness against microbial pathogens. In recent years, researchers have focused on identifying and validating plant-derived compounds for the treatment of various ailments (19). It is worth noting that Indian medicinal plants are considered a valuable source of pharmacologically active compounds, which are frequently used to address a wide range of health conditions. Many pharmacologically active chemicals have already been extracted and identified from essential medicinal herbs such as neem, turmeric, and various other herbs (20). In line with this, the Indian plant known as Bael (Aegle marmelos (L.) Cor.), which has a long history of traditional use in the treatment of various ailments, was selected for preliminary evaluation of its antimicrobial activity against E. faecalis in this study.

In this context, the present study demonstrated a promising antimicrobial effect against E. faecalis, which was consistent with earlier studies where a 5% concentration of A. marmelos extract showed significant antimicrobial activity (21). However, in the present study, antibacterial activity was observed within the concentration range of 5 mg to 20 mg. In contrast, a study conducted by Subhashini A et al., did not observe any antimicrobial activity against E. faecalis (13). These correlating and contrasting results could be attributed to variations in techniques, solvents used, and the strains employed in the studies. Nevertheless, the promising results of the present study are noteworthy as the activity was evaluated against drug-resistant strains of E. faecalis.

To further evaluate the potential, an in-silico approach was employed to assess the drug-ligand interactions between five different compounds of A. marmelos and the EfbA protein of E. faecalis. The drug-likeness assessment based on the molinspiration results appeared promising, with no violations observed for any of the chosen biocompounds. However, two violations were identified for the control compound, erythromycin. Coumarin exhibited the lowest molecular weight among the chemicals, while marmeline had the highest molecular weight of 351.4. Coumarin and its analogs are known for their antimicrobial activity (22). The molecular weights of the other substances ranged from 200 to 370. In terms of hydrogen bond donor and acceptor properties, marmeline had the highest number of rotatable bonds, approximately 8, and the highest miLogP value of 4.32. An important evaluation parameter is the Topological Polar Surface Area (TPSA) value, which indicates the oral bioavailability of a drug and should be >140. Encouragingly, all five chosen bioactive compounds had TPSA values exceeding 140. When comparing overall docking energies, coumarin exhibited the least hydrogen bonds, followed by aegeline, marmeline, imperatorin, and xanthotoxol. Aegeline displayed a binding energy of approximately -6.75, while coumarin had the lowest binding energy of -5.1. Aegeline also exhibited the lowest inhibition constant, whereas coumarin had the highest. Marmeline demonstrated higher levels of torsional, electrostatic, and ligand efficiency.

Purified compounds like imperatorin are known for their antimicrobial activity, as reported from various other plants (23). In the present study, imperatorin exhibited four hydrogen bond contacts, seven van der Waals interactions, two pi-alkyl interactions, and one pi-pi stacking interaction, indicating the stabilisation of binding structures. Aegeline showed four hydrogen bonds, followed by xanthotoxol with three hydrogen bonds, coumarin with two hydrogen bonds, and marmeline with one hydrogen bond interaction. Marmeline displayed the highest van der Waals interaction, followed by imperatorin. Aegeline and marmeline showed the highest pi-sigma interaction. Marmeline and imperatorin exhibited stronger pi-alkyl interactions. Only xanthotoxol and imperatorin displayed pi-pi stacked interactions. Considering all these interactions, aegeline is considered the most promising candidate for further analysis.

In dental and other healthcare settings, where E. faecalis is prevalent with resistant and virulent traits, the implementation of novel drugs can serve as an excellent alternative treatment strategy. From a clinical perspective, periodic surveillance activities on the prevalence of these strains can be conducted. Additionally, computational analysis can be utilised to design novel drugs from various natural sources, screening for potent bioactive compounds to address complications caused by these pathogens.

Limitation(s)

With a promising antibacterial activity of the crude extract of A. marmelos against E. faecalis, authors did not proceed with further purification analysis for the biocompounds. Additionally, the values for Minimal Inhibitory Concentration (MIC) and Minimal Bactericidal Concentration (MBC) were not determined. Further experimental evaluation of the purified compounds is needed to elucidate their toxicity and inhibitory activity.

Conclusion

The current investigation has shown the presence of EfbA among MDR strains of E. faecalis, which may require frequent monitoring in dental and hospital settings. A. marmelos demonstrated a good antimicrobial effect against EfbA-producing strains of E. faecalis. Computational studies revealed a stronger interaction between aegeline and EfbA. However, further experimental validation must be performed for in-vivo inhibitory and toxicity studies to develop aegeline from A. marmelos as a promising drug.

References

1.
Selleck EM, Van Tyne D, Gilmore MS. Pathogenicity of Enterococci. Microbiol Spectr. 2019;7(4):01-38. [crossref][PubMed]
2.
Tleyjeh IM. Temporal trends in infective endocarditis: A population-based study in Olmsted County, Minnesota. The J of the Am Med Asso. 2005;293(24):3022-28. [crossref][PubMed]
3.
Cattaneo C, Rieg S, Schwarzer G, Müller M, Blümel B, Kern W. Enterococcus faecalis bloodstream infection: Does infectious disease specialist consultation make a difference? Infection. 2021;49(6):1289-97. [crossref][PubMed]
4.
Komiyama EY, Lepesqueur LS, Yassuda CG, Samaranayake LP, Parahitiyawa NB, Balducci I, et al. Enterococcus species in the oral cavity: Prevalence, virulence factors and antimicrobial susceptibility. PLoS One. 2016;11(9):e0163001. [crossref][PubMed]
5.
Jouko S, Xu Y, Nallapareddy S, Murray B, Höök M. A family of putative MSCRAMMs from Enterococcus faecalis. Microbiology. 2004;150(7):2069-78. [crossref][PubMed]
6.
Torelli R. The PavA-like fibronectin-binding protein of Enterococcus faecalis, EfbA, is important for virulence in a mouse model of ascending urinary tract infection. J Infect Dis. 2012;15(6):952-60. [crossref][PubMed]
7.
Singh KV. The fibronectin-binding protein EfbA contributes to pathogenesis and protects against infective endocarditis caused by enterococcus faecalis. Infect Immun. 2015;83(12):4487-94. [crossref][PubMed]
8.
Venthodika A. Bioactive compounds of Aegle marmelos L., Medicinal values and its food applications: A critical review. Phytother Res. 2021;35(4):1887-907. [crossref][PubMed]
9.
Mathivadani V, Smiline AS, Priyadharsini JV. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA-1) with Murraya koengii bio-compounds: An in-silico approach. Acta Virol. 2020;64(1):93-99. [crossref][PubMed]
10.
Jayavarsha V, Smiline Girija AS, Gunasekaran S, Vijayashree Priyadharsini J. Characterisation of vancomycin resistant enterococci and drug ligand interaction between vanA of E. faecalis with the bio-compounds from Aegles marmelos. J Pharmacopuncture. 2023;26(3):247-56. [crossref][PubMed]
11.
CLSI guidelines 2021; M100: Performance standards for antimicrobial susceptibility testing, March 2021, Ed.31.
12.
Ahmad W, Amir M, Ahmad A, Ali A, Ali A, Wahab S, et al. Aegle marmelos leaf extract phytochemical analysis, cytotoxicity, in-vitro antioxidant and antidiabetic activities. Plants (Basel). 2021;10(12):2573. [crossref][PubMed]
13.
Subhashini A, Leburu A, Krishnamurthy M, Naveen Kumar V, Nehrudas P. Antibacterial efficacy of Acacia nilotica, Aegle marmelos herbal extracts against Enterococcus faecalis: An invitro study. Int J Res Med Sci. 2023;11(8):2986-90. [crossref]
14.
RCSB: Research Collaboratory for Structural Bioinformatics (RCSB) protein data bank (http://www.rcsb.org/pdb).
15.
Kumar A, Smiline Girija AS, Vijayashree Priyadharsini J. Targeting prolyl tripeptidyl peptidase from Porphyromonas gingivalis with the bioactive compounds from Rosmarinus officinalis- Asian Biomed (Res Rev News). 2019;13(5):197-203. [crossref]
16.
Sivakumar S, Smiline Girija AS, Vijayashree Priyadharsini J. Evaluation of the inhibitory effect of caffeic acid and gallic acid on tetR and tetM efflux pumps mediating tetracycline resistance in Streptococcus sp., using computational approach. Journal of King Saud University- Science. 2020;32(1):904-09. [crossref]
17.
Smiline Girija AS, Ganesh PS. Functional biomes beyond the bacteriome in the oral ecosystem. Jpn Dent Sci Rev. 2022;58:217-26. [crossref][PubMed]
18.
Karimi A, Ghalavand Z, Fallah F, Eslami P, Parvin M, Alebouyeh M, et al. Prevalence of virulence determinants and antibiotic resistance patterns of Enterococcus faecalis strains in patients with community-acquired urinary tract infections in Iran. Int J Environ Health Res. 2018;28(6):599-608. [crossref][PubMed]
19.
Sarojini K, Arivarasu L, Girija AS. Herbal formulation: Review of efficacy, safety, and regulations. Int J Res Pharmac Sci. 2020;11:1506-10. [crossref]
20.
Vaishnavi S, Preetha Chaly, Smiline Girija AS, Raghuraman R, Pandisuba K, Priyadharsini V. Antimicrobial activity of Gotukola leaves and neem leaves: A comparative in-vitro study. Int J of Ayurveda and Holisitc Medicine. 2015;3(3):11-15.
21.
Surender LR, Sainath D, Rakesh Reddy C, Laxmi Gayathri TV, Naveen Kumar B, Chandrasekhar S. Evaluation of antimicrobial efficacy of herbal extracts (Tridax procumbens and Aegle Marmelos) and 5% sodium hypochlorite as irrigants against Enterococcus faecalis: An in-vitro study. Indian J Dent Adv. 2018;10(4):149-54. [crossref]
22.
Cheke R, Patel H, Patil V, Ansari IA, Ambhore J, Shinde S, et al. Molecular insights into coumarin analogues as antimicrobial agents: Recent developments in drug discovery. Antibiotics (Basel). 2022;11(5):566-72. [crossref][PubMed]
23.
Lakshmanan G, Altemimi A, Sivaraj, Selvakumar J, Karthik L, Saravanan K, et al. Imperatorin from the aerial parts of Cleome viscosa L.: A characterisation study and evaluation of the antibacterial activity. Nat Prod Res. 2023;28:01-08.

DOI and Others

DOI: 10.7860/JCDR/2024/66306.18973

Date of Submission: Jun 29, 2023
Date of Peer Review: Sep 13, 2023
Date of Acceptance: Nov 11, 2023
Date of Publishing: Jan 01, 2024

AUTHOR DECLARATION:
• Financial or Other Competing Interests: None
• Was Ethics Committee Approval obtained for this study? Yes
• Was informed consent obtained from the subjects involved in the study? Yes
• For any images presented appropriate consent has been obtained from the subjects. NA

PLAGIARISM CHECKING METHODS:
• Plagiarism X-checker: Jul 01, 2023
• Manual Googling: Sep 22, 2023
• iThenticate Software: Nov 09, 2023 (8%)

ETYMOLOGY: Author Origin

EMENDATIONS: 6

JCDR is now Monthly and more widely Indexed .
  • Emerging Sources Citation Index (Web of Science, thomsonreuters)
  • Index Copernicus ICV 2017: 134.54
  • Academic Search Complete Database
  • Directory of Open Access Journals (DOAJ)
  • Embase
  • EBSCOhost
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Google
  • Popline (reproductive health literature)
  • www.omnimedicalsearch.com